{
    "eid": "2-s2.0-84958116683",
    "title": "Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation",
    "cover-date": "2016-03-01",
    "subject-areas": [
        {
            "$": "Pharmacology",
            "@code": "3004"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        }
    ],
    "keywords": [
        "CNI minimization",
        "CYP3A5",
        "Genetic polymorphism",
        "Kidney transplant",
        "Tacrolimus",
        "Therapeutic drug monitoring"
    ],
    "authors": [
        "Khemjira Yaowakulpatana"
    ],
    "citedby-count": 24,
    "ref-count": 25,
    "ref-list": [
        "Immunosuppression: Evolution in practice and trends, 1994-2004",
        "Tacrolimus: A further update of its use in the management of organ transplantation",
        "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part i",
        "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II",
        "Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus",
        "Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression",
        "Genetic variability in CYP3A5 and its possible consequences",
        "Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism",
        "Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients",
        "Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation",
        "CYP3A5 Polymorphism in Mexican Renal Transplant Recipients and its Association with Tacrolimus Dosing",
        "The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation",
        "CYP3A5 *1 allele: Impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients",
        "Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients",
        "Drug Interaction Facts",
        "Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions",
        "Frequencies of CYP3A5 genotypes and haplotypes in a Korean population",
        "Thai J Pharmacol",
        "CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations",
        "CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study",
        "Low systemic exposure to tacrolimus correlates with acute rejection",
        "Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation",
        "Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection",
        "Optimization of initial tacrolimus dose using pharmacogenetic testing"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Ramathibodi Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Astellas Pharma (Thailand) Co., Ltd.",
        "Chulalongkorn University"
    ]
}